M. Bernard et al., Long-term follow-up of allogeneic bone marrow transplantation in patients with poor prognosis non-Hodgkin's lymphoma, BONE MAR TR, 23(4), 1999, pp. 329-333
Citations number
23
Categorie Soggetti
Hematology,"Medical Research Diagnosis & Treatment
Relapsed or very aggressive high-grade NHL and refractory low-grade NHL hav
e a poor clinical outcome. Autologous BMT may be used but is of limited eff
icacy in these eases, Allogeneic BMT offers the advantage of tumour-free bo
ne marrow and a possible GVL effect, Between 1987 and 1996, 13 patients (me
dian age 31 years) suffering from lymphoid malignancies underwent allo-BMT.
Four patients had low-grade NHL, three intermediate-grade and six high-gra
de NHL, Three patients were grafted with evolutive disease, four were in pa
rtial remission after several courses of chemotherapy, two were in CR2 and
four were in CR1 after initial therapy. The mean number of prior treatments
was 2.7 (1-6), Median time from diagnosis to BMT was 25 months (4-90). The
conditioning regimen consisted of cyclophosphamide (120 mg/kg/day for all,
plus VP16 in one case) and total body irradiation. Five out of the seven p
atients who were not in CR at the time of transplantation entered CR after
BMT, Eight patients developed acute GVHD grade greater than or equal to II
and four had chronic GVHD. Nine patients are alive, eight in CR with a medi
an follow-up of 49.8 months post BMT (2-125), Overall survival is 67.3% and
the median time for EFS is 102 months, Two patients with low-grade NHL rel
apsed 61 and 102 months post BMT and were treated with DLI, One patient wit
h a stage IV SLL had a partial remission and one with multiple cutaneous lo
calisation of FL entered CR after grade IV acute GVHD, Allo-BMT is a highly
effective treatment for advanced poor prognosis lymphoid malignancies with
acceptable toxicity. Moreover, DLI can be effective in relapsing patients.